Urocortin 1
Overview
Urocortin 1 is a 40-amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. It binds to both CRF receptor 1 and CRF receptor 2 with high affinity, mediating diverse cardiovascular effects including vasodilation, positive inotropy, and cardioprotection. The peptide has demonstrated beneficial hemodynamic properties and anti-inflammatory actions in preclinical models of heart failure and ischemia-reperfusion injury.
Key Research Findings
Early phase clinical trials have evaluated urocortin 1 infusion in heart failure patients, demonstrating hemodynamic improvements including increased cardiac output and reduced systemic vascular resistance. However, no large-scale efficacy trials have been completed, and development for cardiovascular indications remains investigational.
Intravenous
Investigational
Interested in Urocortin 1?
Find a verified provider experienced with Urocortin 1 protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Urocortin 1 ProviderRelated Peptides
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets.
Nesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.
Angiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release. Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors.
Serelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked by disulfide bonds. It acts via the relaxin family peptide receptor 1 (RXFP1) to promote vasodilation, inhibit fibrosis, and modulate hemodynamics. The therapeutic rationale targets acute heart failure by improving renal perfusion and reducing vascular resistance.